Eln cml milestones Score — Free Online oncology Calculator

ELN CMLMolecular Milestone Assessment

TKI Response Metrics

Time on Therapy

BCR-ABL1 Level% (IS)

Awaiting Molecular PCR

Enter the molecular response to see if the patient is hitting the ELN targets.

Targets (Optimal)

3 Months: <= 10%
6 Months: <= 1%
12 Months: <= 0.1% (MMR)

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Monitoring patients with CML in Chronic Phase on any TKI (Imatinib, Dasatinib, etc.).

Dictating when to switch TKIs or perform BCR-ABL1 kinase domain mutation analysis.

Requires quantitative RT-PCR for BCR-ABL1 transcripts expressed on the International Scale (IS).

How it Works

ELN Milestones (BCR-ABL1 IS %)

Timepoint	Optimal	Warning	Failure
3 Months	≤ 10%	> 10%	N/A (check again at 6mo)
6 Months	≤ 1%	> 1 - 10%	> 10%
12 Months	≤ 0.1% (MMR)	> 0.1 - 1%	> 1%
Any time	Maintenance of MMR	Loss of MMR	Loss of CHR or CCyR

Last Comprehensive Review: 2026

ELN CMLMolecular Milestone Assessment

TKI Response Metrics

Time on Therapy

BCR-ABL1 Level% (IS)

Awaiting Molecular PCR

Enter the molecular response to see if the patient is hitting the ELN targets.

Targets (Optimal)

3 Months: <= 10%
6 Months: <= 1%
12 Months: <= 0.1% (MMR)

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Monitoring patients with CML in Chronic Phase on any TKI (Imatinib, Dasatinib, etc.).

Dictating when to switch TKIs or perform BCR-ABL1 kinase domain mutation analysis.

Requires quantitative RT-PCR for BCR-ABL1 transcripts expressed on the International Scale (IS).

How it Works

ELN Milestones (BCR-ABL1 IS %)

Timepoint	Optimal	Warning	Failure
3 Months	≤ 10%	> 10%	N/A (check again at 6mo)
6 Months	≤ 1%	> 1 - 10%	> 10%
12 Months	≤ 0.1% (MMR)	> 0.1 - 1%	> 1%
Any time	Maintenance of MMR	Loss of MMR	Loss of CHR or CCyR

Last Comprehensive Review: 2026

ELN CML Milestones

TKI Response Metrics

When to Use

Clinical Use

How it Works

ELN Milestones (BCR-ABL1 IS %)

Clinical Pearls

The 3-Month Early Molecular Response (EMR)

Failure vs. Warning

The Evidence

Key Reference

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Related Tools

Recent Journal Updates

ELN CML Milestones

TKI Response Metrics

When to Use

Clinical Use

How it Works

ELN Milestones (BCR-ABL1 IS %)

Clinical Pearls

The 3-Month Early Molecular Response (EMR)

Failure vs. Warning

The Evidence

Key Reference

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Related Tools

Recent Journal Updates